Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF)’s James Graham discusses promising results from the company’s recent phase 1 clinical safety trial evaluating subjects intravenously dosed with RECCE® 327. The trial is ongoing, as Recce is seeking to discover the ceiling dose of its treatment, attempting to define at which point RECCE® 327 produces an adverse effect in patients.
Recce Pharmaceuticals highlights positive safety data from RECCE® 327 IV trial
